Homepage>Company>Media>Pharma News>2018>Phase II clinical study of elenbecestat demonstraytes safety and tolerability in MCI and mild to moderate Alzheimer’s disease at 18 months
Phase II clinical study of elenbecestat demonstraytes safety and tolerability in MCI and mild to moderate Alzheimer’s disease at 18 months